David Ricks, CEO, Eli Lilly
Scott Mlyn | CNBC
Eli Lilly said on Monday patients have been dosed to test its potential antibody treatment designed to fight COVID-19, caused by the new coronavirus.
The study will assess safety and tolerability in patients hospitalized with COVID-19 and results are anticipated by the end of June, the company said in a statement.
No comments:
Post a Comment